FrancophonIA/ELRC3.0 huggingface dataset:
English: Other common side effects include chest pain, cough and muscle cramps.
Estonian: Muud sagedad kõrvalnähud on valu rinnus, köha ja lihasekrambid.
English: What measures are being taken to ensure the safe and effective use of Oslif Breezhaler?
Estonian: Mis meetmed võetakse, et tagada ravimi Oslif Breezhaler ohutu ja efektiivne kasutamine?
English: Oslif Breezhaler capsules, which contain a powder for inhalation, are only used with a Oslif Breezhaler inhaler and must not be swallowed.
Estonian: Ravimi Oslif Breezhaler kapsleid, mis sisaldavad inhalatsioonipulbrit, tohib kasutada üksnes ravimi Oslif Breezhaler inhalaatoris ja neid ei tohi alla neelata.
English: In three main studies involving over 4,000 patients with COPD, Oslif Breezhaler was compared with placebo (a dummy treatment), tiotropium or formoterol (other inhaled medicines used to treat COPD).
Estonian: Kolmes põhiuuringus, milles osales üle 4000 kroonilise obstruktiivse kopsuhaigusega patsiendi, võrreldi Oslif Breezhalerit platseebo (näiv ravim), tiotroopiumi ja formoterooliga (muud kroonilise obstruktiivse kopsuhaiguse raviks kasutatavad inhaleeritavad ravimid).
English: The Agency also noted that there were no major safety concerns with Oslif Breezhaler, with side effects being manageable and similar to other beta-2 adrenergic receptor agonist medicines.
Estonian: Ravimiamet märkis samuti, et ravimiga Oslif Breezhaler ei ole täheldatud suuri ohutusprobleeme ning ravimi kõrvalnähud on hallatavad ja sarnanevad teiste beeta-2-adrenergilise retseptori agonistide kõrvalnähtudega.
English: Oslif Breezhaler is used for maintenance (regular) treatment.
Estonian: Ravimit Oslif Breezhaler kasutatakse säilitusraviks (tavaliseks raviks).
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Oslif Breezhaler have been included in the summary of product characteristics and the package leaflet.
Estonian: Ravimi Oslif Breezhaler ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: On average, the increase in FEV1 in patients who received Oslif Breezhaler was between 150 to 190 ml, while for patients who received placebo the change in FEV1 ranged from a decrease of 10 ml to an increase of 20 ml.
Estonian: FEV1 suurenes keskmiselt 150-190 ml võrra ravimit Oslif Breezhaler saanud patsientidel ja vähenes kuni 10 ml võrra või suurenes kuni 20 ml võrra platseebot saanud patsientidel.
English: The most common side effects with Oslif Breezhaler (which may affect more than 1 in 10 people) are nasopharyngitis (inflammation of the nose and throat) and upper respiratory tract infection (infection of the nose and throat).
Estonian: Ravimi Oslif Breezhaler kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on nasofarüngiit (nina- ja kurgupõletik) ja ülemiste hingamisteede infektsioon.
English: What is Oslif Breezhaler and what is it used for?
Estonian: Mis on Oslif Breezhaler ja milleks seda kasutatakse?
English: Oslif Breezhaler is a medicine that is used to keep the airways open in adults with chronic obstructive pulmonary disease (COPD).
Estonian: Oslif Breezhaler on ravim, mida kasutatakse hingamisteede avatuna hoidmiseks kroonilise obstruktiivse kopsuhaigusega täiskasvanutel.
English: The active substance in Oslif Breezhaler, indacaterol, is a beta-2 adrenergic receptor agonist.
Estonian: Ravimi Oslif Breezhaler toimeaine indakaterool on beeta-2-adrenergilise retseptori agonist.
English: This is a summary of the European public assessment report (EPAR) for Oslif Breezhaler.
Estonian: See on ravimi Oslif Breezhaler Euroopa avaliku hindamisaruande kokkuvõte.
English: For more information about treatment with Oslif Breezhaler, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate ravimiga Oslif Breezhaler toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Why is Oslif Breezhaler approved?
Estonian: Miks Oslif Breezhaler heaks kiideti?
English: For practical information about using Oslif Breezhaler, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate ravimi Oslif Breezhaler kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: It is not intended to provide practical advice on how to use Oslif Breezhaler.
Estonian: Hindamisaruandes ei anta ravimi Oslif Breezhaler kasutamise praktilisi nõuandeid.
English: Other information about Oslif Breezhaler
Estonian: Muu teave ravimi Oslif Breezhaler kohta
English: For the full list of all side effects and restrictions with Oslif Breezhaler, see the package leaflet.
Estonian: Ravimi Oslif Breezhaler kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Oslif Breezhaler indacaterol
Estonian: Oslif Breezhaler indakaterool
English: When Oslif Breezhaler is inhaled, indacaterol reaches the receptors in the airways and activates them.
Estonian: Ravimi Oslif Breezhaler inhaleerimisel puutub indakaterool kokku hingamisteedes olevate retseptoritega ja aktiveerib need.
English: The European Medicines Agency concluded that Oslif Breezhaler was shown to be effective at improving the lung function in COPD.
Estonian: Euroopa Ravimiamet järeldas, et ravimi Oslif Breezhaler efektiivsus kopsutalitluse parandamisel kroonilise obstruktiivse kopsuhaiguse korral on tõendatud.
English: How does Oslif Breezhaler work?
Estonian: Kuidas Oslif Breezhaler toimib?
English: What are the risks associated with Oslif Breezhaler?
Estonian: Mis riskid ravimiga Oslif Breezhaler kaasnevad?
English: How is Oslif Breezhaler used?
Estonian: Kuidas ravimit Oslif Breezhaler kasutatakse?
English: Oslif Breezhaler was more effective than placebo at improving how well the lungs work in patients with COPD.
Estonian: Oslif Breezhaler oli kroonilise obstruktiivse kopsuhaigusega patsientide kopsutalitluse parandamisel platseebost efektiivsem.
English: What benefits of Oslif Breezhaler have been shown in studies?
Estonian: Milles seisneb uuringute põhjal ravimi Oslif Breezhaler kasulikkus?
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom21 November 2014
Estonian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
English: The full European Public Assessment Report for Ceprotin can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Ceprotini kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What is Ceprotin?
Estonian: Mis on Ceprotin?
English: ‘Acquired' means that the disease is not inherited but develops during the patient's life and may occur for different reasons such as severe infection, liver disease or vitamin K deficiency.
Estonian: „Omandatud” tähendab seda, et haigus ei ole pärilik, vaid kujuneb patsiendi elu jooksul ja võib tekkida erinevatel põhjustel, nagu raske nakkus, maksahaigus või K-vitamiini vaegus.
English: Detailed information on the approved use of Ceprotin in the European Union (EU) can be found here.
Estonian: Üksikasjalik teave Ceprotini heakskiidetud kasutuse kohta Euroopa Liidus on siin.
English: The withdrawal letter is available here.
Estonian: Kiri, milles teatatakse taotluse tagasivõtmisest, on siin.
English: In its letter notifying the Agency of the withdrawal of application, the company stated that it withdrew the application because in its preliminary assessment the CHMP was requesting additional clinical data to support the claim that Ceprotin is also effective in patients with acquired protein C deficiency.
Estonian: Oma kirjas, milles ta teavitas ametit taotluse tagasivõtmisest, väitis ettevõte, et võttis taotluse tagasi, sest inimravimite komitee nõudis oma esialgses hinnangus täiendavaid kliinilisi andmeid, toetamaks väidet, et Ceprotin toimib ka omandatud proteiin C vaegusega patsientidel.
English: On 22 October 2014, Baxter AG officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a new indication for Ceprotin to treat acquired protein C deficiency.
Estonian: Baxter AG teatas 22. oktoobril 2014 ametlikult inimravimite komiteele oma soovist võtta tagasi ravimi Ceprotin uue näidustuse taotlus, mis käsitleb omandatud proteiin C vaeguse ravi.